These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25649862)

  • 21. Multidrug efflux pumps: the structures of prokaryotic ATP-binding cassette transporter efflux pumps and implications for our understanding of eukaryotic P-glycoproteins and homologues.
    Kerr ID; Jones PM; George AM
    FEBS J; 2010 Feb; 277(3):550-63. PubMed ID: 19961540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidrug resistance in cancer: role of ATP-dependent transporters.
    Gottesman MM; Fojo T; Bates SE
    Nat Rev Cancer; 2002 Jan; 2(1):48-58. PubMed ID: 11902585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curcumin as chemosensitizer.
    Limtrakul P
    Adv Exp Med Biol; 2007; 595():269-300. PubMed ID: 17569216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug distribution, resistance to cytostatics and disease pathogenesis: many roles of ABC proteins].
    Lehmann S; Rane A
    Lakartidningen; 2004 Jan; 101(4):282-7. PubMed ID: 14979001
    [No Abstract]   [Full Text] [Related]  

  • 25. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
    Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
    Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug resistance in lung cancer].
    Harada T; Hara N
    Nihon Rinsho; 2002 May; 60 Suppl 5():317-21. PubMed ID: 12101680
    [No Abstract]   [Full Text] [Related]  

  • 30. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
    Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
    Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
    Assaraf YG
    Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
    Ivnitski-Steele I; Larson RS; Lovato DM; Khawaja HM; Winter SS; Oprea TI; Sklar LA; Edwards BS
    Assay Drug Dev Technol; 2008 Apr; 6(2):263-76. PubMed ID: 18205550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells.
    Pituch-Noworolska A; Zaremba M; Wieczorek A
    Pol J Pathol; 2009; 60(4):168-73. PubMed ID: 20072950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.
    McIntosh K; Balch C; Tiwari AK
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):633-44. PubMed ID: 27116192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
    Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
    Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
    Modok S; Mellor HR; Callaghan R
    Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming multidrug resistance in human cancer cells by natural compounds.
    Nabekura T
    Toxins (Basel); 2010 Jun; 2(6):1207-24. PubMed ID: 22069634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
    van der Pol MA; Broxterman HJ; Pater JM; Feller N; van der Maas M; Weijers GW; Scheffer GL; Allen JD; Scheper RJ; van Loevezijn A; Ossenkoppele GJ; Schuurhuis GJ
    Haematologica; 2003 Feb; 88(2):134-47. PubMed ID: 12604403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance molecules: lessons from oncology.
    Scheffer GL; Scheper RJ
    Novartis Found Symp; 2002; 243():19-31; discussion 31-7, 180-5. PubMed ID: 11990777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marine natural products as breast cancer resistance protein inhibitors.
    Cherigo L; Lopez D; Martinez-Luis S
    Mar Drugs; 2015 Apr; 13(4):2010-29. PubMed ID: 25854646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.